Blood tests may reveal who will respond to melanoma immunotherapy
NCT ID NCT05105100
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study examined blood and tumor samples from 25 people with advanced melanoma to understand why some respond to the immunotherapy drug pembrolizumab while others do not. Researchers analyzed T cells—key immune cells—to find genetic and behavioral clues that predict treatment success. No new treatments were tested; the goal was to gather knowledge to improve future care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.